Low-level laser therapy for zymosan-induced arthritis in rats: Importance of illumination time.
BACKGROUND
It has been proposed for many years that low-level laser (or light) therapy (LLLT) can ameliorate the pain, swelling, and inflammation associated with various forms of arthritis. Light is thought to be absorbed by mitochondrial chromophores leading to an increase in adenosine triphosphate (ATP), reactive oxygen species and/or cyclic AMP production and consequent gene transcription via activation of transcription factors. However, despite many reports about the positive effects of LLLT in arthritis and in medicine in general, its use remains controversial. For all indications (including arthritis) the optimum optical parameters have been difficult to establish and so far are unknown.


METHODS
We tested LLLT on rats that had zymosan injected into their knee joints to induce inflammatory arthritis. We compared illumination regimens consisting of a high and low fluence (3 and 30 J/cm(2)), delivered at high and low irradiance (5 and 50 mW/cm(2)) using 810-nm laser light daily for 5 days, with the positive control of conventional corticosteroid (dexamethasone) therapy.


RESULTS
Illumination with 810-nm laser was highly effective (almost as good as dexamethasone) at reducing swelling and a longer illumination time (10 or 100 minutes compared to 1 minute) was more important in determining effectiveness than either the total fluence delivered or the irradiance. LLLT induced reduction of joint swelling correlated with reduction in the inflammatory marker serum prostaglandin E2 (PGE2).


CONCLUSIONS
LLLT with 810-nm laser is highly effective in treating inflammatory arthritis in this model. Longer illumination times were more effective than short times regardless of total fluence or irradiance. These data will be of value in designing clinical trials of LLLT for various arthritides.
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Ana P
AP
Castano
Tianhong
T
Dai
Ilya
I
Yaroslavsky
Richard
R
Cohen
William A
WA
Apruzzese
Michael H
MH
Smotrich
Michael R
MR
Hamblin
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001168:Arthritis / Q000097:blood / Q000139:chemically induced / Q000628:therapy*; D003907:Dexamethasone / Q000627:therapeutic use; D015232:Dinoprostone / Q000097:blood; D004195:Disease Models, Animal; D004307:Dose-Response Relationship, Radiation; D005260:Female; D028022:Low-Level Light Therapy; D011134:Polysaccharides / Q000009:adverse effects; D051381:Rats; D011917:Rats, Inbred Lew; D013997:Time Factors; D015054:Zymosan / Q000009:adverse effects
D000893:Anti-Inflammatory Agents; D011134:Polysaccharides; D003907:Dexamethasone; D015054:Zymosan; D015232:Dinoprostone